Proceeds of the financing will support the global commercial launch of the industry's first fully automated gene synthesis platform, further development of solutions that consolidate synthetic biology workflows, and the expansion of automated Gibson Assembly applications, including an instrument that converts digitized DNA code to biological entities and a novel suite of DNA data storage solutions.
In addition to the continuous commercial licensing of SGI-DNA's Gibson Assembly intellectual property estate, comprising over 50 issued patents, the company will accelerate the development of innovative solutions, including the DBC System (Digital-to-Biological Converter) for on-demand printing of biological materials such as therapeutics and vaccines, and proprietary approaches to DNA synthesis and DNA data storage.
Leveraging their Gibson Assembly Technology, SGI-DNA is well positioned to emerge as a leader in digital synthetic biology.
At SGI-DNA, our mission is to develop revolutionary synthetic genomics platforms that accelerate advances in drug discovery, precision medicine, DNA data storage and industrial design; bridging the gap between the digital and biological worlds.
Founded in 2014, SGI-DNA was officially spun out of Synthetic Genomics, Inc. in March of 2019.
Merck launches Phase 3 trial for dengue vaccine candidate V181
BioNet and Bio Farma sign MoU on TdaP vaccine
Dx&Vx accelerates universal COVID-19 vaccine development
Moderna withdraws application for flu-COVID combination vaccine pending additional efficacy data
CTP delivers 18,000 sqm Serbian facility for SCHOTT Pharma to support global expansion
LakeShore Biopharma launches novel packaging solution for YSJA rabies vaccine (Vero cell)
Scancell partners with NHS Cancer Vaccine Launch Pad to accelerate melanoma trial recruitment
Orexo reports positive results for powder-based intranasal vaccine using AmorphOX technology
GC Biopharma's BARYTHRAX receives Korean regulatory approval
GSK grants USD2m to boost adult vaccination efforts
Valneva and LimmaTech begin Phase 2 infant trial for Shigella vaccine candidate S4V2
Circio Holding and Entos Pharmaceuticals collaborate on circular RNA delivery
AKAGERA Medicines completes first cohort in phase 1 SAD/MAD study of AKG-100